Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Agnieszka Gierczak-Pachulska"'
Autor:
Agnieszka Gierczak-Pachulska, Michał Kaza, Katarzyna Jarus-Dziedzic, Olga Czerepow-Bielik, Agnieszka Segiet-Święcicka, Grzegorz Huszcza, Katarzyna Sidoruk, Daniel Rabczenko, Piotr J. Rudzki
Publikováno v:
Acta Poloniae Pharmaceutica, Vol 81, Iss 1, Pp 97-108 (2024)
Rivaroxaban is an oral anticoagulant that is a selective, direct factor Xa inhibitor. It is used to prevent thrombotic events of atherosclerotic etiology and to prevent stroke and peripheral embolism in adult patients with nonvalvular atrial fibrilla
Externí odkaz:
https://doaj.org/article/316b5d2cc8424ab39a49b99e3bb9ff89
Autor:
Maciej Wieczorek, Piotr J. Rudzki, Katarzyna Jarus-Dziedzic, Agnieszka Gierczak-Pachulska, Katarzyna Bazydlo-Guzenda
Publikováno v:
Diabetes. 70
Activation of GPR40 (G-protein coupled receptor 40) in pancreatic β-cells may improve glycaemic control in type 2 diabetes (T2D) patients through enhancement of glucose-stimulated insulin secretion (GSIS). Here we present phase I an open label, dose
Publikováno v:
Journal of Medical Science. 2023, Vol. 92 Issue 3, p55-58. 4p.
BIOEQUIVALENCE OF RIVAROXABAN HARD CAPSULES VS. FILM-COATED TABLETS IN HEALTHY CAUCASIAN VOLUNTEERS.
Autor:
GIERCZAK-PACHULSKA, AGNIESZKA, KAZA, MICHAŁ, JARUS-DZIEDZIC, KATARZYNA, CZEREPOW-BIELIK, OLGA, SEGIET-ŚWIĘCICKA, AGNIESZKA, HUSZCZA, GRZEGORZ, SIDORUK, KATARZYNA, RABCZENKO, DANIEL, RUDZKI, PIOTR J.
Publikováno v:
Acta Poloniae Pharmaceutica; Jan/Feb2024, Vol. 81 Issue 1, p97-108, 12p
Publikováno v:
Genomics & Genetics Weekly; 10/21/2024, p402-402, 1p